During your consultation, well explain which option may be appropriate for you, what to expect, and how we monitor your progress for safety and results
Licensed in 45 states
Patients carrying the GLP1R rs6923761 variant, for example, may require dose adjustments or complementary agents to achieve target weight loss, while others with GIPR rs1800437 variants show enhanced response to tirzepatide dual-agonist therapy
'This isn't a failing of the medicines - it reflects the nature of obesity as a chronic, relapsing condition
Russo G, Mischi M, Scheepens W, De la Rosette JJ, Wijkstra H
Changes in metabolic hormones after bariatric surgery and their predictive impact on weight loss